667 results about "Coronavirus Infections" patented technology

The present disclosure provides antibodies and antigen-binding fragments thereof that bind specifically to a coronavirus spike protein and methods of using such antibodies and fragments for treating or preventing viral infections (e.g., coronavirus infections).

The invention relates to a preparation method for a vaccine capable of treating and/ or preventing SARS-CoV-2 infection or COVID-19 diseases. The core antigen of the vaccine comprises the RBD (receptor binding zone) fusion protein of the SARS-CoV-2, and a vaccine form comprises an RBD fusion protein subunit vaccine, an RBD fusion protein mRNA vaccine or an RBD fusion protein adenovirus vector vaccine. The above vaccine immunizes an organism, and immune reaction for treating and/ or preventing the SARS-CoV-2 infection can be generated so as to be used for treating and/ or preventing COVID-19. The invention also relates to an RBD fusion gene, the RBD fusion protein, a carrier, a cell, a preparation method, a treatment method or a pharmacy purpose of the SARS-CoV-2.

Provided are compounds, methods and pharmaceutical compositions for treating a host, especially a human, infected with a togavirus, herpes virus and/or coronavirus, and in particular SARS-CoV, cytomegalovirus or varicella-zoster virus. The method in one embodiment comprises administering to that host an effective amount of an anti-togavirus, anti-herpes virus and/or anti-coronavirus phospholipid or a pharmaceutically acceptable salt or prodrug thereof. The phospholipid compound is, e.g., a 3-alkylamido-2-alkoxypropylphosphocholine compound or salt thereof. The compound may be administered alone or in combination and/or alternation with one or more other anti-viral agents.

The invention provides methods of preventing and/or treating infection by a respiratory virus such as respiratory syncytial virus (RSV) and SARS-associated coronavirus, particularly reducing infection and/or one or more symptoms of respiratory virus infection. A polynucleotide comprising an immunostimulatory sequence (an "ISS") is administered to an individual which is at risk of being exposed to a respiratory virus, has been exposed to a respiratory virus or is infected with a respiratory virus. The ISS is administered without any antigens of the respiratory virus. Administration of the ISS results in reduced incidence and/or severity of one or more symptoms of respiratory virus infection.

The invention discloses a fusion protein of a novel coronavirus envelope protein and an application of the fusion protein. The fusion protein (SARS2-RBD-Fc) is obtained by fusing an RBD structural domain of a novel coronavirus envelope protein S with an antibody Fc fragment; and as a subunit vaccine, the fusion protein can induce an organism to generate an efficient neutralizing antibody through nasal drip immunization and intramuscular injection. It indicates that the SARS2-RBD-Fc can be used as a candidate vaccine for preventing and treating new coronavirus infection.

The invention relates to traditional Chinese medicine compositions, and specifically discloses a prescription capable of treating pneumonia caused by 2019-nCoV (a novel coronavirus) infection as wellas application thereof. The prescription capable of treating the pneumonia caused by the 2019-nCoV infection comprises the following traditional Chinese medicine materials as raw materials in parts byweight: 9 parts of ephedra, 6 parts of roasted liquorice roots, 9 parts of apricot kernels, 15-30 parts of raw gypsum, 9 parts of cassia twigs, 9 parts of oriental waterplantain rhizome, 9 parts of zhuling, 9 parts of white atractylodes rhizomes, 15 parts of poria cocos, 16 parts of radix bupleuri, 6 parts of baical skullcap roots, 9 parts of ginger processed pinellia tubers, 9 parts of fresh ginger, 9 parts of aster, 9 parts of common coltsfoot flowers, 9 parts of blackberry lily rhizome, 6 parts of manchurian wildginger, 12 parts of Chinese yams, 6 parts of immature orange fruits, 6 parts of dried orange peel, and 9 parts of wrinkled gianthyssop herb. In combination with symptom manifestation of the pneumonia caused by the 2019-nCoV infection, the invention adopts an optimized and integrated traditional Chinese medicine prescription, thereby achieving synergistic treatment effects. According to current treatment results of diagnosed patients of different ages in many provinces and regions, the prescription capable of treating the pneumonia caused by the 2019-nCoV infection has true curative effects that the response rate is up to 95.12%.

The present invention belongs to the field of biomedicine, and relates to polypeptides capable of inhibiting human coronavirus infections, particularly to polypeptides capable of inhibiting human coronavirus infections in a broad spectrum manner, and applications thereof. According to the present invention, the polypeptides capable of providing broad spectrum inhibition effects for infections caused by more than 2 human coronaviruses are provided based on the conservation property of the S2 region of a coronavirus S protein and the similar fusion mechanism; the test results show that the polypeptides can achieve the commonality of the human coronavirus, ie., the similar HR region and the same fusion mechanism mediated by the coronavirus S protein so as to provide a series of HCoV-EK polypeptides, wherein the polypeptides provide good inhibition effects for currently popular human coronaviruses, and further provide good inhibition activity for SARS virus (RsSHC014-CoV or RsW1V1-CoV) possibly infecting human; and the polypeptides of the present invention can provide the prevention and treatment candidate drug for the currently popular human coronaviruses and the novel human coronavirus possibly emerging in the future.

The present disclosure relates to compositions and methods for treating or preventing coronavirus infections. For example, compositions are provided that comprise a coronavirus S protein or N protein, fragment, or variant thereof, capable of eliciting a protective humoral and/or cell-mediated immune response, which compositions are useful for treating or preventing infection by coronavirus, such as the causative agent of SARS. Also, coronavirus S protein and N protein immunogen compositions are provided that include an adjuvant, such as Proteosome or Protollin, which may be used for treating or preventing infection caused by a coronavirus, such as a SARS coronavirus.

The invention relates to an application of nucleoside analogs in virus resistance. Specifically, the invention relates to the use of nucleoside analogs and pharmaceutical compositions thereof as (a) inhibitors for inhibiting the replication of coronavirus, influenza virus, respiratory syncytial virus, flaviviridae virus, filoviridae virus and/or porcine epidemic diarrhea virus (PEDV); and/or (b) medicines for treating and/or preventing and relieving related diseases caused by infection of coronavirus, influenza virus, respiratory syncytial virus, flaviviridae virus, filoviridae virus and/or porcine epidemic diarrhea virus (PEDV). The nucleoside analogue disclosed by the invention can be used for treating and/or preventing and relieving related diseases such as respiratory tract infection, pneumonia (COVID-19) and the like caused by 2019 novel coronavirus infection.

The invention discloses an isolated novel coronavirus monoclonal antibody or an antigen binding part thereof. The monoclonal antibody is specifically bound to S protein of the novel coronavirus. The monoclonal antibody contains a heavy chain variable region of SEQ ID NO.1-3 amino acid sequences and a light chain variable region of SEQ ID NO.5-7 amino acid sequences. The monoclonal antibody can beused to detect the existence of the novel coronavirus. In addition, the monoclonal antibody has neutralizing activity, so that can be used for the development of drugs for preventing or treating novelcoronavirus infection.

The invention relates to a protein for resisting SARS-CoV-2 infection and a vaccine, and belongs to the field of medicines. The problem of lack of effective prevention and treatment drugs for SARS-CoV-2 infection is solved. On one hand, the protein for resisting SARS-CoV-2 infection contains a structural domain combined with an angiotensin converting enzyme 2 receptor in an S protein of SARS-CoV-2, and the first amino acid arginine at the N end of the structural domain can be deleted. On the other hand, the vaccine for preventing and/or treating the SARS-CoV-2 infection contains the protein for resisting the SARS-CoV-2 infection, and pharmaceutically acceptable auxiliary materials or auxiliary components. According to the protein for resisting SARS-CoV-2 infection and the vaccine, the combination of the S protein of the SARS-CoV-2 and an ACE2 receptor of a host cell is blocked by inducing in-vivo generation of antibodies and other immune responses, so that a host is helped to resist coronavirus infection.

The invention discloses a biological product for preventing novel coronavirus (COVID-19). The biological product can be a gene vaccine or gene medicine, wherein the gene vaccine adopts a human type-5adenovirus with deletion of E1 and E3 genes as a vector for carrying an S1 protein antigen for expressing a Spike S1 subunit of the novel coronaviruses or simultaneously carrying an S1 expression protein antigen and N protein antigen. Through in-vivo expression of antigen proteins, the immune reaction of a body upon the novel coronavirus can be stimulated, and the effect of preventing infection and propagation of the novel coronavirus.

The present invention provides methods for treating a coronavirus infection. For example, treatment may be effected by administering a neurotransmitter inhibitor, a signaling kinase inhibitor, an estrogen receptor inhibitor, a DNA metabolism inhibitor or an anti-parasitic agent. Also provided are methods for treating a coronavirus infection in which an anti-viral drug also is administered during any of the described methods.

The invention discloses a polypeptide for inhibiting novel coronavirus infection and a screening method thereof, which belong to the technical field of biological medicine. The screening method comprises the following steps: obtaining an S protein gene sequence of the novel coronavirus SARS-CoV-2; determining an HR1 region and an HR2 region of an S protein region of the novel coronavirus SARS-CoV-2; selecting a natural peptide fragment consisting of 30-36 amino acids in the HR2 region as a polypeptide for inhibiting novel coronavirus infection; on the basis of the natural peptide fragment, glutamic acid-lysine or glutamic acid-arginine pairs are designed through site-specific mutagenesis to form a polypeptide chain inner salt bridge. Compared with the prior art, the polypeptide for inhibiting the novel coronavirus infection has the beneficial effects that the polypeptide for inhibiting the novel coronavirus infection can form a stable 6-HB spiral structure with HR1P and has the capability of inhibiting the novel coronavirus infection from invading cells.

The invention relates to a nucleic acid detection kit for novel coronavirus COVID-19. The kit comprises a first primer pair and a first probe which correspond to Cov-n, and a second primer pair and asecond probe which correspond to Cov-ORF1ab. The kit disclosed by the invention can be used for simultaneously carry out multiple-gene and multiple-site detection on the novel coronavirus, so that thedetection accuracy is improved; and in addition, when the multiple fluorescence PCR reaction is carried out, novel coronavirus detection information can be provided through one-time detection within70 minutes, so that the diagnosis time of the novel coronavirus COVID-19 is shortened. The kit can be used for in vitro qualitatively detecting throat swabs, sputum and bronchoalveolar lavage fluid samples of suspected pneumonia cases infected by the novel coronavirus, suspected aggregated case patients, and other diagnosis people who are required to perform novel coronavirus infection diagnosis or identification.

The invention discloses a reagent kit for detecting novel coronaviruses and influenza viruses at the same time. The reagent kit disclosed by the invention specially comprises a primer probe for separately targeting S genes, E genes, N genes and/or ORF1ab genes of novel coronaviruses, and a primer probe for targetting characteristic consensus sequence of the influenza viruses A/B, and novel coronavirus RNA for qualitatively detecting pneumonia suspected cases and suspected clustered cases of patients infected with the novel coronaviruses, or other novel coronavirus RNA for diagnosing infectionof the novel coronaviruses or identifying novel coronavirus RNA in other samples of nasopharyngeal swabs, sputamentum and the like of diagnostician, and besides, the reagent kit is used for detectingRNA of influenza viruses A/B in the samples to assist in elimination of suspected cases, can be used for identifying and diagnosing infection with the novel coronaviruses, and is high in sensitivity and convenient to use.

The invention discloses an immunochromatographic kit used for detecting novel coronavirus SARS-CoV-2 infection. The kit comprises a test strip. The test strip comprises a sample pad, a combination pad, a chromatography membrane and an absorption pad which are correspondingly pasted and laminated, and the combination pad is coated with a colloidal gold labeled neopterin antibody conjugate, a novelcoronavirus N protein conjugate, a novel coronavirus S1 protein conjugate and a DNP-BSA conjugate. A quality control line C and a detection line are arranged on the NC membrane. The C line is coated with a rabbit anti-DNP antibody, the detection line comprises a T1 line, a T2 line and a T3 line. The T1 line and the T2 line are respectively coated with one of an anti-human IgG antibody and an anti-human IgM antibody. The T3 line is coated with a Neo-BSA antigen, and the C line, the T1 line and the T2 line are three parallel bands perpendicular to the long side of the test strip. The kit provided by the invention is beneficial to early diagnosis and rapid confirmation of novel coronavirus infection, and has high sensitivity.

Provided are a detection reagent and a kit. The reagent detects a 2019-coronavirus SARS-CoV-2 immunoglobulin A (SARS-CoV-2 IgA) antibody in blood and a salivary liquefied sugar chain antigen KL-6 at the same time, and is used for screening, especially for early screening of 2019-coronavirus infected pneumonia, and for pre-judging the detection reagent for severe patients. The kit comprises a testcard, and the test card is composed of an SARS-CoV-2 IgA test strip, a KL-6 test strip and a plastic box. The reagent and the kit disclosed by the invention can be used for diagnosing the new coronavirus pneumonia at an earlier stage and can be used for judging whether a patient suffering from the new coronavirus pneumonia has lung injury or not.

The invention relates to application of azithromycin to preparation of anti-coronavirus-infection medicine, and application of a medicine composition containing azithromycin to preparation of anti-coronavirus-infection medicine or combined application of azithromycin and other antiviral medicine.

The invention discloses a recombinant RBD trimer protein capable of simultaneously generating cross neutralization activity aiming at multiple novel coronavirus (SARS-CoV-2) epidemic strains, the trimer protein is composed of subunits of three novel coronavirus S protein RBD regions, and the amino acid sequences of the three novel coronavirus RBD regions are the same or at least one is different; and when the amino acid sequences of the three novel coronavirus RBD regions are the same, the amino acid sequences are the amino acid sequences shown as SEQ ID No.2 or SEQ ID No.3, or sequences with more than 95% of homology with the amino acid sequences shown as SEQ ID No.2 or SEQ ID No.3. The RBD trimer protein is taken as an antigen and supplemented with an adjuvant to immunize an organism, so that a high-titer neutralizing antibody aiming at various novel coronavirus epidemic strains can be generated at the same time, and the antibody has certain broad spectrum and can be used for treating and/or preventing novel coronavirus infection and/or novel coronavirus diseases.

The invention belongs to the field of biological medicine and provides a polypeptide. The polypeptide contains a sequence as shown in SEQ ID No. 9 and has an inhibitory effect on novel coronavirus HCoV-EMC/2012 infection. The invention also provides to a nucleic acid molecule coding the polypeptide, related recombinant protein, a nucleic acid molecule, an expression vector and a recombinant cell. A medicine can be prepared from the polypeptide provided by the invention and frequently medically acceptable carrier, excipient or the like for prevention and inhibition of novel coronavirus HCoV-EMC/2012 infection; and polypeptide can also be combined with other medicines. The invention provides candidate polypeptide medicines for prevention or treatment of novel coronavirus HCoV-EMC/2012 infection.

The present invention provides a method for treating coronavirus infections in cats or other animals by administering a nucleoside represented by a formula (I) and a corresponding prodrug, solvate, orpharmaceutically acceptable salt thereof, a pharmaceutical composition comprising the compound, wherein the nucleoside and the prodrug thereof in the formula (I) are in alpha configuration, and R1, R2, R3 and R4 are all defined in the specification. The formula (I) is defined in the specification.

The invention provides a novel coronavirus detection test strip as well as a preparation method and application thereof. The test strip comprises a binding pad and an analysis membrane, and the binding pad is coated with a luminescent substance labeled 2019-nCoV recombinant antigen and a mouse anti-human HCG monoclonal antibody; a T2 detection line, a T1 detection line and a quality control line are sequentially arranged on the analysis membrane along the chromatography direction; the T2 detection line is coated with a mouse anti-human IgG monoclonal antibody, the T1 detection line is coated with a mouse anti-human IgA monoclonal antibody and a mouse anti-human IgM monoclonal antibody, and the quality control line is coated with a goat anti-mouse IgG polyclonal antibody. The test paper card can simultaneously determine the positive conditions of IgA antibody, IgM antibody and IgG antibody in serum of a patient, can more accurately detect the early antibody level condition in the body of the patient, assists in judging different periods of novel coronavirus infection of the patient, and improves the sensitivity and specificity of novel coronavirus detection.

The present invention relates to methods of detecting the presence or absence of antibody to SARS coronavirus in a sample, based on the discovery that the S, M, E, N and U274 proteins of SARS coronavirus are antigenic. Such methods may be used to diagnose whether a patient has been infected by or exposed to SARS coronavirus. Antibodies directed against S, M, E, N and U274 proteins of SARS are also provided.

The invention discloses a novel coronavirus T cell epitope peptide, pMHC and the preparation and application thereof. The amino acid sequence of the novel coronavirus T cell epitope peptide is as shown in any one of SEQ ID NO: 1-9. According to the invention, nine novel coronavirus T cell epitope peptides are discovered; the pMHC compound monomer is prepared by using the pMHC compound; the pMHC complex polymer can be used for detecting antigen-specific T cells in peripheral blood of a novel coronavirus infected rehabilitative person and used for an in-vitro T cell activation experiment, and the novel coronavirus T cell epitope peptides can be applied to immunodetection related to novel coronaviruses.